| WAT |
Report |
Total revenue |
BEAT |
pred ~$1.642B vs. cons $1.624B |
MEDIUM |
| WAT |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$3.11 vs. cons $3.008 |
MEDIUM |
| WAT |
Report |
Chemistry revenue |
IN-LINE |
pred ~$173.0M vs. cons $171.9M |
MEDIUM |
| WAT |
Guide |
FY26 total revenue |
UNCHANGED |
guide ~$6.405B-$6.455B vs. cons $6.445B |
MEDIUM |
| WAT |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$14.40-$14.60 vs. cons $14.522 |
MEDIUM |
| WAT |
Guide |
Q3 adjusted EPS |
UNCHANGED |
guide ~$3.95-$4.05 vs. cons $3.996 |
LOW |
| WAT |
Guide |
Forward commentary |
UNCHANGED |
reiterate synergy/cost-savings timing; cautious BD China tone vs. UNVERIFIED comparator |
LOW |
| WAT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| WAT |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — B-type package with limited out-period revision |
LOW |